Ilika plc MOU signed with Cirtec Medical (7279M)
16 Enero 2023 - 1:00AM
UK Regulatory
TIDMIKA
RNS Number : 7279M
Ilika plc
16 January 2023
Ilika plc
("Ilika" or the "Company")
Memorandum of understanding signed with Cirtec Medical
Partnership to collaborate in the manufacturing and
commercialisation of miniature Stereax solid-state batteries
Ilika (AIM: IKA), a pioneer in solid-state battery technology,
announces it has broadened its relationship with Cirtec Medical
('Cirtec'), an industry-leading strategic outsourcing partner of
complex medical devices including minimally invasive and active
implantable devices, by signing a memorandum of understanding
('MOU') which outlines the transfer of Stereax mm-scale battery
manufacturing to Cirtec's facility in Lowell, Massachusetts,
U.S.
Ilika will focus on advanced technology development and IP
licensing in support of Cirtec's manufacturing and
commercialisation activities. This partnership will reinforce
Cirtec's ongoing activities in system level miniaturisation for the
medical device industry. Benefits of this partnership, to Ilika,
include:
-- Further validation of Stereax's capabilities
-- Manufacturing partnership delivering economy of scale and ability to rapidly ramp production
-- Expanded business development team bringing additional commercial momentum
In due course Ilika and Cirtec envisage signing a contract once
the terms of the partnership have been finalised and a further
announcement will be made at this time.
Graeme Purdy, Ilika's Chief Executive Officer, said: "Our
partnership with Cirtec reinforces a pathway towards
commercialisation of our Stereax battery technology. Cirtec brings
a wealth of manufacturing experience and a strong track record of
successful product commercialisation in the medical device
industry."
Brian Highley, Cirtec Medical Chief Executive Officer,
commented: "With over 20 years of experience in the design,
development and manufacturing of medical devices, Cirtec is
uniquely poised to work with Ilika in bringing its Stereax battery
technology to market. We believe this collaboration fits right into
our strengths and expands upon our mission to vertically integrate
our capabilities to support our offerings to the implantable and
wearable device markets."
For more information contact:
Ilika plc www.ilika.com
Graeme Purdy, Chief Executive Via Walbrook PR
Jason Stewart, Chief Financial Officer
Liberum Capital Limited (Nomad Tel: 020 3100 2000
and Joint Broker)
Andrew Godber, Cameron Duncan,
William Hall, Nikhil Varghese
Joh. Berenberg, Gossler & Co. KG Tel: 020 3207 8700
(Joint Broker)
Matthew Armitt, Mark Whitmore, Detlir
Elezi,
Mara Grasso
Walbrook PR Ltd Tel: 020 7933 8780 / Ilika@walbrookpr.com
Lianne Applegarth Mob: 07584 391 303
Nick Rome Mob: 07748 325 236
About Ilika Technologies
Ilika specializes in the development of solid-state batteries.
Its Stereax product line is designed for miniature medical implants
and specialist internet of Things (IoT) applications. Stereax
enables disruptive product designers looking for an intrinsically
safe, long life (1000s recharges), low leakage (nA) and miniature
power source in a rectangular form factor similar to ICs. For more
information about Ilika, please visit: https://www.ilika.com.
About Cirtec Medical
Cirtec Medical is a vertically integrated, full-service
outsource partner providing end-to-end product design, development
and manufacturing of Class III and II medical devices and
components. Cirtec specialize in today's most advanced product
technologies including, neuromodulation, implantable drug delivery,
cardiac rhythm management, ventricular assist and minimally
invasive systems including TAVR/TMVR. Cirtec has a global footprint
with facilities in Brooklyn Park, MN; Chandler, AZ; Enfield, CT;
San Jose CA, Lowell, MA, Coyal Free Zone, Costa Rica and
Birkenfeld, Germany.
Ilika will be presenting at the Medical Battery Conference on
February 7, 2023 at the MD&M West Show in Anaheim , CA and will
be present on the Cirtec stand during the show.
The information contained within this announcement is deemed by
the Company to constitute inside information for the purposes of
Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations
2019/310. Upon the publication of this announcement via a
Regulatory Information Service ("RIS"), this inside information is
now considered to be in the public domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEASFDFSLDEFA
(END) Dow Jones Newswires
January 16, 2023 02:00 ET (07:00 GMT)
Ilika (AQSE:IKA.GB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Ilika (AQSE:IKA.GB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024